The PICOPLUS has demonstrated safety and efficacy in this well-designed study, which is in line with other articles on the ps-laser in the literature. Additionally, I am excited about the added benefits demonstrated with the use of the combined wavelength approach.
(PRWEB) December 04, 2017
The study authors compared the combined treatment of 2% hydroquinone (HQ) cream and dual wavelength picosecond laser (ps-laser) treatment (1064 nm and 595 nm) (ps-laser + HQ) to using 2% HQ cream alone in a split-face trial protocol. Two percent HQ is already an accepted treatment and was used as the control. The lightness index (LI),as measured objectively by a colorimeter, was used to assess the improvement between the two different treatment sides. The averaged LI scores of the PICOPLUS + HQ sides showed a significant decrease compared with the control HQ-treated sides, denoting an improvement in the melasma lesions. No side effects were reported by patients or clinicians.
In addition to the superior LI scores for the ps-laser + HQ treatment, some other things of note were mentioned: recurrence rates, a consistent problem with melasma treatment, were relatively low: this is thought to be related to the dual wavelength protocol utilized in this study. In addition, there was a noted reduction in erythema as a side effect: this is believed to have a direct correlation to the 595 nm visible yellow wavelength in what Lutronic refers to as PICO gold toning.
“The PICOPLUS has demonstrated safety and efficacy in this well-designed study, which is in line with other articles on the ps-laser in the literature,” stated Dr. Glen Calderhead, VP of Lutronic Medicoscientific Affairs. “Additionally, I am excited about the added benefits demonstrated with the use of the combined wavelength approach.” The reduction in side effects, number of treatments needed and low reoccurrence rates clearly demonstrate the efficacy of the PICOPLUS protocol for treating melasma in Korean skin types.
About PICOPLUS
The PICOPLUS platform offers both picosecond and nanosecond modes with the additional benefit of four wavelengths to provide physicians with more options than ever before to address everything from the standard treatments for pigmented lesions, to those hard-to-treat cases resistant to other Nd:YAG approaches, and with clinical practice further extended to include skin rejuvenation and scar revision offered by the new dual-wavelength focused dots handpiece. This CE-marked device delivers the customized power, pulsewidth, wavelength and fluence clinicians need to achieve the outstanding outcomes that patients want, all from one premium platform. PICOPLUS represents the next generation on from our PICO+4.
- Four wavelengths for best versatility (1064, 532, 595 and 660 nm)
- Dual pulse modes (choice of pico- and nanosecond) for optimized treatment options
- High energy output together with stable low energy output for 532 nm treatments
- Pulsewidth of 450 ps with a maximum of 800 mJ at 1064 nm: 1.78 GW peak power
- Wide-range of precisely controllable fluence options
- 5 handpieces (including the new Dual-wavelength Focused Dots)
- Convenient features, such as built-in storage
For more information about PICOPLUS
visit: https://int.aesthetic.lutronic.com/intl/products/picoplus/
About LUTRONIC
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 20 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, rejuvenation, body/face contouring, chronic pain, healing and more.
With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 200 current and pending patents worldwide. With more than 270 employees worldwide, Lutronic has offices in the US, Europe, Korea, China, and Japan, a world-wide network of distributors, focused R&D centers in Korea, and is ever expanding.
For more information about Lutronic visit: http://www.lutronic.com